Welcome to our dedicated page for Quest Diagnostics Incorporated news (Ticker: $DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics Incorporated stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Quest Diagnostics Incorporated's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Quest Diagnostics Incorporated's position in the market.
Ruth Clements, East Region President of Quest Diagnostics, spoke at the National Action Network Convention about addressing health inequities. She emphasized the importance of routine diagnostic testing in bridging healthcare gaps, particularly in the Black community. Clements highlighted Quest's initiatives, including the launch of Quest for Health Equity (Q4HE) in 2020, which aims to reduce health disparities through improved access to testing and screenings. In 2023, Q4HE conducted over 6,000 no-cost Blueprint for Wellness tests in marginalized communities.
Quest Diagnostics celebrated Lab Week 2024 from May 21, 2024, recognizing their medical laboratory professionals and pathologists nationwide. The event showcased inspiring professional journeys of Quest colleagues, including Deepika Kumar, who evolved from a Lab Assistant to an Associate Scientist over 11 years in Lewisville, Texas. Deepika highlighted her motivation for financial independence, joy in cytogenetics, and the importance of continuous improvement. She shared her career progression, emphasizing the role of Quest's training programs and a supportive work environment in her professional growth.
Quest Diagnostics (NYSE: DGX) announced the election of Robert B. Carter, CIO of FedEx , to its Board of Directors. With this addition, Quest's Board now comprises 10 members. Carter, 64, boasts over 31 years at FedEx, where he oversaw technology direction and infrastructure. He will retire from his roles in June but will stay on as an advisor until December. This strategic move aims to leverage Carter's expertise in technology, cloud, and cybersecurity to drive Quest's growth and IT initiatives. Quest's leadership highlighted the valuable insights Carter brings, acknowledging his extensive public and private board experience.
Quest Diagnostics (NYSE: DGX) has announced that its Board of Directors has declared a quarterly cash dividend of $0.75 per share.
This dividend will be payable on July 22, 2024, to shareholders who hold Quest Diagnostics common stock as of July 8, 2024.
Quest Diagnostics is recognized as a leader in diagnostic information services.
The Quest Diagnostics Drug Testing Index for 2023 reveals a substantial increase in workforce drug test tampering, with tampered specimens surging over six-fold compared to the previous year. The report, analyzing nearly 9.8 million tests, shows a 633% rise in substituted specimens and a 45.2% increase in invalid specimens. General U.S. workforce drug positivity remained high at 5.7%, while marijuana positivity rose to 4.5%—a 45.2% increase over five years. Post-accident marijuana positivity reached a new peak of 7.5% in 2023. In contrast, federally mandated, safety-sensitive workforce marijuana positivity saw a slight decrease. Other notable trends include increased drug positivity among office-based industries and a rise in cocaine positivity. Meanwhile, opiates and heroin metabolite positivity showed a decline.
Quest Diagnostics celebrated Lab Week 2024 across the nation. The event featured the professional journeys of colleagues, like Javarus Smith, who progressed from Route Service Representative to Logistics Manager. Javarus emphasized the impact of their work on patients' lives and encouraged flexibility for career growth within Quest. The company's commitment to customer service, care, collaboration, continuous improvement, and curiosity was highlighted.
Quest Diagnostics received high praise from a patient at their Voorhees PSC location in New Jersey, highlighting exceptional staff service and professionalism. The team's dedication and consistent excellent service reflect the company's core values. The positive feedback showcases a strong commitment to customer care and satisfaction.
Quest Diagnostics, a leading diagnostic information services company, will have its CEO speak at the 2024 Leerink Partners Healthcare Crossroads Conference. The event will cover the company's strategy, performance, and market trends, with a live webcast available for investors.
Quest Diagnostics and PathAI announced a collaboration to accelerate the adoption of digital and AI pathology innovations to improve cancer diagnosis. Quest will acquire select assets of PathAI Diagnostics to enhance its AI and digital capabilities. The transaction is expected to be completed in the second quarter of 2024. Additionally, Quest will license PathAI's AISight™ digital pathology image management system to support its pathology laboratories and customer sites in the U.S.
Quest Diagnostics has appointed Murali Balakumar as the Senior Vice President and Chief Information and Digital Officer, bringing 25 years of experience in technology strategy across healthcare, financial services, and transportation industries. As a digital transformation leader, Mr. Balakumar will oversee information technology, data informatics, and digital solutions for the company.
